Project Grant R01HL176891
Award Date 9/5/25
Completion Date 5/31/29
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
William Penn Annex West, PA 19107, USA
Similar Awards
- This federal Project Grant award of $552,413.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Thomas Jefferson University's Sidney Kimmel Medical College. The grant will support research over a period of 4 years, from April 1, 2025 to January 31, 2029, with the goal of investigating siRNA-mediated in vivo knockdown of key regulators of platelet and megakaryocyte function, including the P2Y12 receptor,...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $779,952 project grant to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to investigate the role of platelets in regulating non-neurological complications of ischemic stroke. The 4-year project, running from June 2025 to March 2029, aims to gain a deeper understanding of how activated platelets contribute to remote organ injury and...
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...
- This $604,301 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Versiti Wisconsin, Inc. will support research on membrane-cytoskeleton interactions in megakaryocytes and platelets. The research aims to advance the understanding of abnormal platelet production and function, which can pose significant clinical risks including bleeding and thrombotic events. The project will investigate the precise molecular mechanisms...
- This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...
- The Project Grant award titled "PAI-1, TPA, TFPI AND ENDOMETRIAL ENDOTHELIAL CELLS IN UTERINE HEMOSTASIS" is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $164,376 award supports research at Oregon Health & Science University to investigate the role of certain coagulation factors and endometrial endothelial cells in uterine hemostasis, with the goal of generating hypotheses for managing heavy...
- This Project Grant award for $445,000.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research conducted by The Children's Hospital of Philadelphia (CHOP) to study the role of neutrophil extracellular traps (NETs) in inflammatory and thrombotic diseases. The project aims to characterize the role of NETs in immune homeostasis, determine the mechanisms by which NET stabilization...
- This Project Grant award for $713,538 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate metabolic reprogramming as a novel therapeutic approach for thrombotic cardiovascular disease. The key objectives are to explore how inhibiting the cytosolic malic enzyme 1 (ME1) in platelets and leukocytes can reduce their hyperactivation and susceptibility to arterial thrombosis, while minimizing bleeding risk compared to...
- The University of Rochester was awarded a $573,261 Project Grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to investigate the role of platelets in regulating monocyte immune responses during vascular inflammation. The 4-year research project, beginning August 1, 2025, aims to understand how resting platelets interact with monocytes to epigenetically "train" their innate immune responses, and how this process is altered by platelet...
- This $498,153 federal Project Grant was awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the Marshall University Research Corporation on August 1, 2025. The project aims to investigate the role of the sodium pump (sodium/potassium ATPase) in platelet function and thrombosis risk, particularly in the context of sex hormone therapy. Using mouse models and in vitro assays, the research will examine how genetic and pharmacological...